Search

Search Constraints

You searched for: Author/Creator Pook, David

Search Results

1. A pro‐tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. Issue 1 (9th July 2014)

2. Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancer. Issue 2 (29th March 2021)

3. Establishing a cryopreservation protocol for patient‐derived xenografts of prostate cancer. Issue 11 (18th June 2019)

4. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Issue 10 (October 2019)

5. Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer. Issue Volume 128:Issue Supplement 1(2021) (7th October 2021)

6. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Issue 4 (April 2023)

7. Treatment outcomes for patients with metastatic castrate‐resistant prostate cancer following docetaxel for hormone‐sensitive disease. Issue 1 (24th September 2020)